Recruiting NCT06445361
Prevalence of NAFLD in T1DM Patients
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: FibroScan.
- Who it may be relevant to
- Registry conditions: NAFLD, Type 1 Diabetes, Fatty Liver, Nonalcoholic. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Belgium
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
The Prevalence of Non-Alcoholic Fatty Liver Disease in Type 1 Diabetes Mellitus Patients Followed at Ziekenhuis Oost-Limburg, Genk, Belgium
Overview
To determine the prevalence of NAFLD in T1DM patients.
Interventions
- Diagnostic test FibroScan
Performance of a FibroScan measurement to determine steatosis and fibrosis.
Primary outcome measures
- Prevalence of NAFLD in T1DM [Time frame: During the intervention]
- Prevalence of fibrosis in T1DM [Time frame: During the intervention]
Eligibility criteria
Inclusion criteria
- T1DM
- ≥ 18 years of age
- Written informed consent obtained
Exclusion criteria
- Excessive alcohol use
- Exclusion of other causes of liver disease and secondary causes of liver steatosis
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Diagnostic
Study locations
Belgium · 1 center
- Ziekenhuis Oost-Limburg — Genk
Identifiers
NCT: NCT06445361 · Z-2022007